---
schema_version: "secwatch.filing_event.v1"
accession: "0001808805-25-000002"
form_type: "8-K"
ticker: "NAUT"
cik: "0001808805"
company_name: "Nautilus Biotechnology, Inc."
filed_at: "2025-01-31T23:59:59+00:00"
generated_at: "2026-05-27T04:47:08.399030+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# Two Nautilus Biotechnology directors not standing for re-election at 2025 annual meeting

## Summary
- Vijay Pande informed company on Jan 27, 2025, that he will not stand for re-election.
- Michael Altman informed company on Jan 28, 2025, that he will not stand for re-election.
- Both directors confirmed departure is not due to any disagreement with company operations, policies, or practices.

## SEC filing metadata
- accession: 0001808805-25-000002
- form_type: 8-K
- ticker: NAUT
- cik: 0001808805
- company_name: Nautilus Biotechnology, Inc.
- filed_at: 2025-01-31T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1808805/000180880525000002/0001808805-25-000002-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1808805/000180880525000002/naut-20250127.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001808805-25-000002
- JSON: https://secwatch.observer/filing/0001808805-25-000002.json
- Plain text: https://secwatch.observer/filing/0001808805-25-000002.txt

## Key facts
- Executive change
  Michael Altman departed as Director at Nautilus Biotechnology, Inc..
  - Action: informed that they will not stand for re-election
  - Role: Director
  source text: On January 27 and 28, 2025, each of Vijay Pande and Michael Altman, respectively, informed Nautilus Biotechnology, Inc. (the “Company”) that they will not stand for re-election to the Company’s board of directors at the Company’s 2025 annual meeting of stockholders.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1808805/000180880525000002/0001808805-25-000002-index.htm
- Executive change
  Vijay Pande departed as Director at Nautilus Biotechnology, Inc..
  - Action: informed that they will not stand for re-election
  - Role: Director
  source text: On January 27 and 28, 2025, each of Vijay Pande and Michael Altman, respectively, informed Nautilus Biotechnology, Inc. (the “Company”) that they will not stand for re-election to the Company’s board of directors at the Company’s 2025 annual meeting of stockholders.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1808805/000180880525000002/0001808805-25-000002-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.